TRN-213 is under clinical development by Tris Pharma and currently in Phase II for Muscle Spasticity. According to GlobalData, Phase II drugs for Muscle Spasticity have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how TRN-213’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TRN-213 overview
TRN-213 is under development for the treatment of spasticity.
Tris Pharma overview
Tris Pharma is a biopharmaceutical company that develops therapies. The company’s pipeline product candidates include TRN-257 which treats narcolepsy; TRN-213 treats spasticity; TRN-218 for pediatric attention-deficit hyperactivity disorder (ADHD); TRN-228 for acute pain, chronic low back pain, chronic neuropathic pain and opioid addiction; TRN-261 which targets pain. Tris Pharma provides digital health pipeline products such as AI-Enhanced Digital ADHD Diagnostic. It offers DYANAVEL XR, Quillivant XR and QuilliChew ER and others. Tris Pharma is headquartered in South Brunswick, New Jersey, the US.
For a complete picture of TRN-213’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
